Spero Therapeutics Announces Presentations at IDWeek 2019
Spero Therapeutics, Inc. (SPRO)
Last spero therapeutics, inc. earnings: 3/16 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.sperotherapeutics.com/overview
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it will present four posters at the Infectious Disease Society of America (IDSA) IDWeek™ 2019 taking place October 2 - 6, 2019 in Washington, DC. Presentations include one poster on the pharmacokinetics-pharmacodynamics of SPR994, Spero’s oral carbapenem antibiotic product candidate currently in a Pivotal Phase 3 clinical trial for the treatment of complicated urinary tract infections (cUTI), and three posters on cUTI epidemiology and antimicrobial susceptibility. Title: Characterization of Tebipenem (SPR859) Pharmacokinetics- Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection ModelPresenter: Bria
Show less
Read more
Impact Snapshot
Event Time:
SPRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRO alerts
High impacting Spero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SPRO
News
- Spero Therapeutics (NASDAQ:SPRO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SPRO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Spero Therapeutics (NASDAQ:SPRO) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SPRO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis [Yahoo! Finance]Yahoo! Finance
- Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisGlobeNewswire
- Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
SPRO
Earnings
- 11/13/25 - Beat
SPRO
Sec Filings
- 12/19/25 - Form 8-K
- 11/12/25 - Form 4
- SPRO's page on the SEC website